Combined intravitreal dexamethasone and bevacizumab injection for the treatment of persistent diabetic macular edema (DexaBe study): a phase I clinical study.
Francyne Veiga Reis CyrinoPedro DalgalarrondoJosé Edisio da Silva Tavares NetoMurilo Wendeborn RodriguesIngrid U ScottRodrigo JorgePublished in: International journal of retina and vitreous (2023)
Treatment of DME refractory to laser and/or anti-VEGF therapy with combined PRN IV dexamethasone aqueous solution and bevacizumab was associated with adverse effects related to the use of corticosteroids. However, there was a significant improvement in CSFT meantime best-correct visual acuity remained stable or improved in 50% of patients.
Keyphrases
- end stage renal disease
- aqueous solution
- vascular endothelial growth factor
- low dose
- high dose
- ejection fraction
- chronic kidney disease
- newly diagnosed
- stem cells
- endothelial cells
- prognostic factors
- peritoneal dialysis
- mass spectrometry
- metastatic colorectal cancer
- diabetic retinopathy
- mesenchymal stem cells
- replacement therapy
- bone marrow